Brief: Fresenius SE - Announces FDA Approval Of Rituximab Biosimilar
03/08/2026 07:31
BRIEF-Fresenius SE - Announces FDA Approval Of Rituximab Biosimilar Aug 3 (Reuters) - Fresenius SE & Co KGaA FREG.DE:
FRESENIUS SE - ANNOUNCES FDA APPROVAL OF RITUXIMAB BIOSIMILAR FOR U.S. MARKET
Further company coverage: FREG.DE
(Gdansk Newsroom)
(((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600);))
Recent news on Fresenius SE & Co. KGaA
See all newsFresenius lifts 2026 expectations after strong Q3 (updated)
Healthcare firm Fresenius Q3 revenue rises on Kabi growth; lifts outlook
Brief: Fresenius Sees FY26 EBIT Margin Above 11.5%
Brief: Fresenius SE Q3 Revenue EUR 5,803 Million
Fresenius signs biosimilars pipeline agreement with WuXi Biologics (updated)